Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.47 |
| ▸ | ACR | P10323 | 1/20 | 0.47 |
| ▸ | GBA1 | P04062 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17301247 | 0.94 | MAPT (0.72) | MAPTKDM4EPOLBMAPK1KMT2A | |
| SCHEMBL20110390 | 0.90 | MAPT (0.52) | MAPTKDM4EPOLBMAPK1KMT2A | |
| SCHEMBL17301248 | 0.89 | KMT2A (0.70) | MAPTKDM4EPOLBMAPK1KMT2A | |
| SCHEMBL14370325 | 0.86 | LMNA (0.57) | MAPTKDM4EPOLBMAPK1KMT2A | |
| SCHEMBL14484181 | 0.86 | LMNA (0.57) | MAPTKDM4EPOLBMAPK1KMT2A | |
| SCHEMBL14370321 | 0.86 | LMNA (0.57) | MAPTKDM4EPOLBMAPK1KMT2A | |
| SCHEMBL17301250 | 0.86 | MAPT (0.61) | MAPTKDM4EPOLBMAPK1KMT2A | |
| SCHEMBL19054604 | 0.84 | LMNA (0.62) | MAPTKDM4EPOLBMAPK1KMT2A | |
| SCHEMBL14370322 | 0.84 | LMNA (0.77) | MAPTKMT2ALMNAPRSS1ACR | |
| SCHEMBL14484261 | 0.84 | LMNA (0.77) | MAPTKMT2ALMNAPRSS1ACR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180119014-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOUND, POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL POLYMERIZED FILMS | JNC CORPORATION (JP) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180119014-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOUND, POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL POLYMERIZED FILMS | NAP1L1, CCNA1, NAP1L4 | MAPT 371/4885KDM4E 2829/4885POLB 1874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.